{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:02:46Z","timestamp":1791388966150,"version":"4.3.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93019C00040"],"award-info":[{"award-number":["75N93019C00040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01451-7","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:16:04Z","timestamp":1777954564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Meredith B.","family":"Finn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Willsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Lyn","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Clendenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskan","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Soee","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukti","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian R.","family":"Laciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Uggowitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Obiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Freeman-Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Pirayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Himansu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linden T.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obadiah","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007744","volume":"7","author":"Y Dong","year":"2022","unstructured":"Dong, Y. et al. Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis. BMJ Glob. Heal. 7, e007744 (2022).","journal-title":"BMJ Glob. Heal."},{"key":"1451_CR2","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/1873-3468.13894","volume":"594","author":"V Dulipati","year":"2020","unstructured":"Dulipati, V., Meri, S. & Panelius, J. Complement evasion strategies of Borrelia burgdorferi sensu lato. FEBS Lett. 594, 2645\u20132656 (2020).","journal-title":"FEBS Lett."},{"key":"1451_CR3","unstructured":"Centers for Disease Control and Prevention, Data and Surveillance. https:\/\/www.cdc.gov\/lyme\/data-research\/facts-stats\/index.html#cdc_data_surveillance_section_2-available-data (2023)."},{"key":"1451_CR4","unstructured":"Lindgren, E. & Jaenson, T. G. T. Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. World Health Organization. Regional Office for Europe (2006)."},{"key":"1451_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.15585\/mmwr.mm6717e1","volume":"67","author":"R Rosenberg","year":"2018","unstructured":"Rosenberg, R. et al. Vital Signs: Trends in Reported Vectorborne Disease Cases \u2014 United States and Territories, 2004\u20132016. Morb. Mortal. Wkly. Rep. 67, 496\u2013501 (2018).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"1451_CR6","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","volume":"2","author":"AC Steere","year":"2016","unstructured":"Steere, A. C. et al. Lyme borreliosis. Nat. Rev. Dis. Prim. 2, 16090 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1451_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.21775\/cimb.042.333","volume":"42","author":"JD Radolf-","year":"2022","unstructured":"Radolf-, J. D., Strle, K., Lemieux, J. E. & Strle, F. Lyme Disease in Humans. Curr. Issues Mol. Biol. 42, 333\u2013384 (2022).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1451_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.idc.2015.02.010","volume":"29","author":"PS Mead","year":"2015","unstructured":"Mead, P. S. Epidemiology of Lyme Disease. Infect. Dis. Clin. North Am. 29, 187\u2013210 (2015).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"1451_CR9","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1073\/pnas.0607263104","volume":"104","author":"MR Scheckelhoff","year":"2007","unstructured":"Scheckelhoff, M. R., Telford, S. R., Wesley, M. & Hu, L. T. Borrelia burgdorferi intercepts host hormonal signals to regulate expression of outer surface protein A. Proc. Natl. Acad. Sci. 104, 7247\u20137252 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1451_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2958.1989.tb00194.x","volume":"3","author":"S Bergstr\u00f6m","year":"1989","unstructured":"Bergstr\u00f6m, S., Bundoc, V. G. & Barbour, A. G. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol. Microbiol. 3, 479\u2013486 (1989).","journal-title":"Mol. Microbiol."},{"key":"1451_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI9427","volume":"106","author":"U Pal","year":"2000","unstructured":"Pal, U. et al. Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A. J. Clin. Investig. 106, 561\u2013569 (2000).","journal-title":"J. Clin. Investig."},{"key":"1451_CR12","doi-asserted-by":"publisher","first-page":"115572","DOI":"10.1016\/j.diagmicrobio.2021.115572","volume":"102","author":"GP Wormser","year":"2021","unstructured":"Wormser, G. P. A brief history of OspA vaccines including their impact on diagnostic testing for lyme disease. Diagn. Micro Infect. Dis. 102, 115572 (2021).","journal-title":"Diagn. Micro Infect. Dis."},{"key":"1451_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/07853890500431934","volume":"37","author":"B Wilske","year":"2005","unstructured":"Wilske, B. Epidemiology and diagnosis of Lyme borreliosis. Ann. Med. 37, 568\u2013579 (2005).","journal-title":"Ann. Med."},{"key":"1451_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJM199807233390402","volume":"339","author":"LH Sigal","year":"1998","unstructured":"Sigal, L. H. et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface Protein A to Prevent Lyme Disease. N. Engl. J. Med. 339, 216\u2013222 (1998).","journal-title":"N. Engl. J. Med."},{"key":"1451_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJM199807233390401","volume":"339","author":"AC Steere","year":"1998","unstructured":"Steere, A. C. et al. Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant. N. Engl. J. Med. 339, 209\u2013215 (1998).","journal-title":"N. Engl. J. Med."},{"key":"1451_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1126\/science.281.5377.703","volume":"281","author":"DM Gross","year":"1998","unstructured":"Gross, D. M. et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme Arthritis. Science 281, 703\u2013706 (1998).","journal-title":"Science"},{"key":"1451_CR17","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1093\/infdis\/jiae230","volume":"230","author":"P Mead","year":"2024","unstructured":"Mead, P., Hinckley, A. & Kugeler, K. Lyme Disease Surveillance and Epidemiology in the United States: A Historical Perspective. J. Infect. Dis. 230, S11\u2013S17 (2024).","journal-title":"J. Infect. Dis."},{"key":"1451_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41579-024-01026-0","volume":"22","author":"WMde Souza","year":"2024","unstructured":"Souza, W. M. de & Weaver, S. C. Effects of climate change and human activities on vector-borne diseases. Nat. Rev. Microbiol. 22, 476\u2013491 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1451_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0183-8","volume":"5","author":"HD Kamp","year":"2020","unstructured":"Kamp, H. D. et al. Design of a broadly reactive Lyme disease vaccine. Npj Vaccines 5, 33 (2020).","journal-title":"Npj Vaccines"},{"key":"1451_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/IAI.00917-19","volume":"88","author":"A Nayak","year":"2020","unstructured":"Nayak, A. et al. Broadly protective multivalent OspA vaccine against Lyme Borreliosis developed based on surface shaping of the C-terminal fragment. Infect. Immun. 88, 1\u201317 (2020).","journal-title":"Infect. Immun."},{"key":"1451_CR21","doi-asserted-by":"publisher","unstructured":"B\u00e9zay, N. et al. Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(23)00210-4. (2023),","DOI":"10.1016\/s1473-3099(23)00210-4"},{"key":"1451_CR22","doi-asserted-by":"publisher","unstructured":"B\u00e9zay, N. et al. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(24)00175-0. (2024).","DOI":"10.1016\/s1473-3099(24)00175-0"},{"key":"1451_CR23","doi-asserted-by":"publisher","unstructured":"Pine, M. et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.022. (2023).","DOI":"10.1016\/j.ymthe.2023.07.022"},{"key":"1451_CR24","doi-asserted-by":"publisher","unstructured":"Tahir, D. et al. Lyme disease mRNA vaccine targeting Borrelia burgdorferi Outer Surface Protein A (OspA) induces strong immune responses and prevents transmission in mice. Mol. Ther. Nucleic Acids 102514 https:\/\/doi.org\/10.1016\/j.omtn.2025.102514. (2025).","DOI":"10.1016\/j.omtn.2025.102514"},{"key":"1451_CR25","doi-asserted-by":"publisher","first-page":"s259","DOI":"10.1093\/cid\/ciq117","volume":"52","author":"AC Steere","year":"2011","unstructured":"Steere, A. C., Drouin, E. E. & Glickstein, L. J. Relationship between Immunity to Borrelia burgdorferi Outer-surface Protein A (OspA) and Lyme Arthritis. Clin. Infect. Dis. 52, s259\u2013s265 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"1451_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00429-5","volume":"7","author":"RJ Dattwyler","year":"2022","unstructured":"Dattwyler, R. J. & Gomes-Solecki, M. The year that shaped the outcome of the OspA vaccine for human Lyme disease. npj Vaccines 7, 10 (2022).","journal-title":"npj Vaccines"},{"key":"1451_CR27","doi-asserted-by":"publisher","unstructured":"Chen, W.-H., Strych, U., Bottazzi, M. E. & Lin, Y.-P. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines (2022) https:\/\/doi.org\/10.1080\/14760584.2022.2102484. (2022).","DOI":"10.1080\/14760584.2022.2102484"},{"key":"1451_CR28","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1073\/pnas.94.8.3584","volume":"94","author":"H Li","year":"1997","unstructured":"Li, H., Dunn, J. J., Luft, B. J. & Lawson, C. L. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. 94, 3584\u20133589 (1997).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1451_CR29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1110\/ps.062246706","volume":"15","author":"K Makabe","year":"2006","unstructured":"Makabe, K., Tereshko, V., Gawlak, G., Yan, S. & Koide, S. Atomic-resolution crystal structure of Borrelia burgdorferi outer surface protein A via surface engineering. Protein Sci. 15, 1907\u20131914 (2006).","journal-title":"Protein Sci."},{"key":"1451_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI144843","volume":"131","author":"ZA Schiller","year":"2021","unstructured":"Schiller, Z. A. et al. Blocking Borrelia burgdorferi transmission from infected ticks to non-human primates with a human monoclonal antibody. J. Clin. Invest. 131, 1\u201312 (2021).","journal-title":"J. Clin. Invest."},{"key":"1451_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1006\/jmbi.2000.4119","volume":"302","author":"W Ding","year":"2000","unstructured":"Ding, W. et al. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA11. Edited by I. A. Wilson. J. Mol. Biol. 302, 1153\u20131164 (2000).","journal-title":"J. Mol. Biol."},{"key":"1451_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1128\/iai.65.3.882-889.1997","volume":"65","author":"WT Golde","year":"1997","unstructured":"Golde, W. T. et al. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun. 65, 882\u2013889 (1997).","journal-title":"Infect. Immun."},{"key":"1451_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/0264-410X(95)00035-Y","volume":"13","author":"BJB Johnson","year":"1995","unstructured":"Johnson, B. J. B. et al. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13, 1086\u20131094 (1995).","journal-title":"Vaccine"},{"key":"1451_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1128\/jcm.31.2.340-350.1993","volume":"31","author":"B Wilske","year":"1993","unstructured":"Wilske, B. et al. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol 31, 340\u2013350 (1993).","journal-title":"J. Clin. Microbiol"},{"key":"1451_CR35","unstructured":"VanHoecke, C., Voet, P., DeGrove, D. & Hansen, P. Immunogenicity of Al(OH)3-adsorbed and plain lipoprotein OspA vaccine formulation in monkeys and man. 34th Interscience Conference on Antimicrobial Agents Chemotherapy, Orlando, Florida (2007)."},{"key":"1451_CR36","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1128\/iai.65.8.3146-3150.1997","volume":"65","author":"AMde Silva","year":"1997","unstructured":"Silva, A. M. de, Fish, D., Burkot, T. R., Zhang, Y. & Fikrig, E. OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks. Infect. Immun. 65, 3146\u20133150 (1997).","journal-title":"Infect. Immun."},{"key":"1451_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1084\/jem.183.1.271","volume":"183","author":"AMde Silva","year":"1996","unstructured":"Silva, A. M. de, Telford, S. R., Brunet, L. R., Barthold, S. W. & Fikrig, E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183, 271\u2013275 (1996).","journal-title":"J. Exp. Med."},{"key":"1451_CR38","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1128\/IAI.73.3.1644-1647.2005","volume":"73","author":"CL Gipson","year":"2005","unstructured":"Gipson, C. L. & Silva, A. M. de. Interactions of OspA Monoclonal Antibody C3.78 with Borrelia burgdorferi within Ticks. Infect. Immun. 73, 1644\u20131647 (2005).","journal-title":"Infect. Immun."},{"key":"1451_CR39","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1128\/IAI.71.2.822-829.2003","volume":"71","author":"S Rathinavelu","year":"2003","unstructured":"Rathinavelu, S., Broadwater, A. & Silva, A. M. de. Does Host Complement Kill Borrelia burgdorferi within Ticks? Infect. Immun. 71, 822\u2013829 (2003).","journal-title":"Infect. Immun."},{"key":"1451_CR40","doi-asserted-by":"publisher","first-page":"e00306-22","DOI":"10.1128\/iai.00306-22","volume":"90","author":"AM Frye","year":"2022","unstructured":"Frye, A. M. et al. Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments. Infect. Immun. 90, e00306-22 (2022).","journal-title":"Infect. Immun."},{"key":"1451_CR41","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.2c00346","author":"HME Haque","year":"2022","unstructured":"Haque, H. M. E. et al. Human B Cell Epitope Map of the Lyme Disease Vaccine Antigen, OspA. Acs Infect. Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.2c00346 (2022).","journal-title":"Acs Infect. Dis."},{"key":"1451_CR42","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1073\/pnas.87.10.3768","volume":"87","author":"UE Schaible","year":"1990","unstructured":"Schaible, U. E. et al. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl. Acad. Sci. 87, 3768\u20133772 (1990).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1451_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamapediatrics.2022.6243","volume":"177","author":"A Watanabe","year":"2023","unstructured":"Watanabe, A. et al. Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years. JAMA Pediatr. 177, 384\u2013394 (2023).","journal-title":"JAMA Pediatr."},{"key":"1451_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1451_CR45","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2025.5646","volume":"333","author":"AKR Spergel","year":"2025","unstructured":"Spergel, A. K. R. et al. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults \u226550 Years. JAMA 333, 1977\u20131987 (2025).","journal-title":"JAMA"},{"key":"1451_CR46","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41591-025-03591-0","volume":"31","author":"AKR Spergel","year":"2025","unstructured":"Spergel, A. K. R. et al. mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1\/2 trial. Nat. Med. 31, 1484\u20131493 (2025).","journal-title":"Nat. Med."},{"key":"1451_CR47","doi-asserted-by":"publisher","first-page":"e1011243","DOI":"10.1371\/journal.ppat.1011243","volume":"19","author":"JE Lemieux","year":"2023","unstructured":"Lemieux, J. E. et al. Whole genome sequencing of human Borrelia burgdorferi isolates reveals linked blocks of accessory genome elements located on plasmids and associated with human dissemination. PLOS Pathog. 19, e1011243 (2023).","journal-title":"PLOS Pathog."},{"key":"1451_CR48","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1128\/iai.61.11.4696-4702.1993","volume":"61","author":"SW Barthold","year":"1993","unstructured":"Barthold, S. W. & Bockenstedt, L. K. Passive immunizing activity of sera from mice infected with Borrelia burgdorferi. Infect. Immun. 61, 4696\u20134702 (1993).","journal-title":"Infect. Immun."},{"key":"1451_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S0264-410X(98)00052-8","volume":"16","author":"CV Hoecke","year":"1998","unstructured":"Hoecke, C. V., Fu, D., Grave, D. D., Voet, P. & Lebacq, E. Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12. Vaccine 16, 1688\u20131692 (1998).","journal-title":"Vaccine"},{"key":"1451_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/JCM.38.1.382-388.2000","volume":"38","author":"TG Schwan","year":"2000","unstructured":"Schwan, T. G. & Piesman, J. Temporal changes in outer surface Proteins A and C of the Lyme Disease-Associated Spirochete, Borrelia burgdorferi, during the Chain of Infection in Ticks and Mice. J. Clin. Microbiol. 38, 382\u2013388 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"1451_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-777X.77298","volume":"3","author":"DA Skibinski","year":"2011","unstructured":"Skibinski, D. A., Baudner, B. C., Singh, M. & O\u2019Hagan, D. T. Combination Vaccines. J. Glob. Infect. Dis. 3, 63\u201372 (2011).","journal-title":"J. Glob. Infect. Dis."},{"key":"1451_CR52","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1067\/mpd.2000.107796","volume":"137","author":"HJ Schmitt","year":"2000","unstructured":"Schmitt, H. J. et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis\u2013hepatitis B virus\u2013 inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J. Pediatr. 137, 304\u2013312 (2000).","journal-title":"J. Pediatr."},{"key":"1451_CR53","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/00006454-200111001-00002","volume":"20","author":"MD DECKER","year":"2001","unstructured":"DECKER, M. D. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J. 20, S10\u2013S18 (2001).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1451_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/0014-5793(79)80578-5","volume":"108","author":"J McCauley","year":"1979","unstructured":"McCauley, J. et al. Influenza virus haemagglutinin signal sequence. FEBS Lett. 108, 422\u2013426 (1979).","journal-title":"FEBS Lett."},{"key":"1451_CR55","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1083\/jcb.103.4.1193","volume":"103","author":"C Doyle","year":"1986","unstructured":"Doyle, C., Sambrook, J. & Gething, M. J. Analysis of progressive deletions of the transmembrane and cytoplasmic domains of influenza hemagglutinin. J. Cell Biol. 103, 1193\u20131204 (1986).","journal-title":"J. Cell Biol."},{"key":"1451_CR56","doi-asserted-by":"publisher","first-page":"eadf4100","DOI":"10.1126\/scitranslmed.adf4100","volume":"15","author":"GBE Stewart-Jones","year":"2023","unstructured":"Stewart-Jones, G. B. E. et al. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Sci. Transl. Med. 15, eadf4100 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1451_CR57","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1073\/pnas.81.8.2327","volume":"81","author":"TJ Bos","year":"1984","unstructured":"Bos, T. J., Davis, A. R. & Nayak, D. P. NH2-terminal hydrophobic region of influenza virus neuraminidase provides the signal function in translocation. Proc. Natl. Acad. Sci. 81, 2327\u20132331 (1984).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1451_CR58","doi-asserted-by":"publisher","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2023","unstructured":"Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1451_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00890-4","volume":"9","author":"MA Wolf","year":"2024","unstructured":"Wolf, M. A. et al. Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice. npj Vaccines 9, 103 (2024).","journal-title":"npj Vaccines"},{"key":"1451_CR60","doi-asserted-by":"publisher","unstructured":"Vance, D. J. et al. Single-domain antibodies reveal unique borrelicidal epitopes on the Lyme disease vaccine antigen, outer surface protein A (OspA). Infect. Immun. e0008424 https:\/\/doi.org\/10.1128\/iai.00084-24 (2024).","DOI":"10.1128\/iai.00084-24"},{"key":"1451_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/infdis\/jiw151","volume":"214","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Pre-exposure Prophylaxis With OspA-specific human monoclonal antibodies protects mice against tick transmission of Lyme Disease Spirochetes. J. Infect. Dis. 214, 205\u2013211 (2016).","journal-title":"J. Infect. Dis."},{"key":"1451_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jviromet.2012.01.003","volume":"181","author":"T Koho","year":"2012","unstructured":"Koho, T. et al. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods 181, 6\u201311 (2012).","journal-title":"J. Virol. Methods"},{"key":"1451_CR63","doi-asserted-by":"publisher","first-page":"101253","DOI":"10.1016\/j.xcrm.2023.101253","volume":"4","author":"CE Deal","year":"2023","unstructured":"Deal, C. E. et al. An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. Cell Rep. Med. 4, 101253 (2023).","journal-title":"Cell Rep. Med."},{"key":"1451_CR64","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 168, 1114\u20131125.e10 (2017).","journal-title":"Cell"},{"key":"1451_CR65","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/bph.15193","volume":"177","author":"NP Sert","year":"2020","unstructured":"Sert, N. P. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 177, 3617\u20133624 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"1451_CR66","doi-asserted-by":"crossref","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 66,125\u2013132 (2010).","DOI":"10.1107\/S0907444909047337"},{"key":"1451_CR67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1107\/S0907444909047374","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D: Biol. Crystallogr. 66, 133\u2013144 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1451_CR68","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D."},{"key":"1451_CR69","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"1451_CR70","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1107\/S2059798323003595","volume":"79","author":"J Agirre","year":"2023","unstructured":"Agirre, J. et al. The CCP4 suite: integrative software for macromolecular crystallography. Acta Crystallogr. D. 79, 449\u2013461 (2023).","journal-title":"Acta Crystallogr. D."},{"key":"1451_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D: Biol. Crystallogr. 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1451_CR72","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D: Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1451_CR73","doi-asserted-by":"publisher","unstructured":"Rudolph, M. J. et al. Structural elucidation of a protective B Cell Epitope on Outer Surface Protein C (OspC) of the Lyme Disease Spirochete, Borreliella burgdorferi. Mbio e02981-22 https:\/\/doi.org\/10.1128\/mbio.02981-22 (2023).","DOI":"10.1128\/mbio.02981-22"},{"key":"1451_CR74","unstructured":"Himansu, S. et al. Lyme disease mRNA vaccines. Patent Application, PCT\/US2024\/023822 (2024)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01451-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:02:35Z","timestamp":1786924955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01451-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01451-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B.F., C.D., L.M., J.M.O., H.N., S.G., E.P., A.R.L., Y.T.L., S.H., A.C., and O.P. are or were employees of Moderna and may hold stock\/stock options in the company. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"167"}}